Why taking the trip out of psychedelic medicine is a mistake

Paper. Heller J, Hendlin YH. The International Journal on Drug Policy, 9 Sep 2026.

Weekly Science Digest, 20 Jul 2026 to 2 Oct 2026, finding 7: Do you need the trip for the benefit?

In a mouse model of autism, one dose of psilocybin made the animals lastingly more social, even when it was given under anesthesia. A second mouse study found psilocybin still helped fear extinction when the 5-HT2A receptor, the one behind the trip, was blocked. A commentary in the International Journal of Drug Policy argues that removing the experience removes much of the therapy.

How much weight it carries: Both findings are in mice. Whether the experience matters in humans is still open. (Mice, Preclinical, Peer reviewed)

Weekly Science Digest, 5 Sep 2026 to 11 Sep 2026, finding 4: Taking the trip out, and an argument against

A PNAS study strips LSD down to its minimal pharmacophore and finds safer, less hallucinogenic analogues.

Nine simplified ergolines were profiled across 5-HT2A/2B/2C; UCD0076 prefers 5-HT2C, shows antipsychotic-like effects in mice and avoids LSD's cardiotoxic liability. A separate report has a non-hallucinogenic LSD analogue boosting anti-tumour immunity in colorectal cancer models.

Read the original

—
Node—
Statuslive
Throughput—